Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SONORX vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 Β· OpiCalc Medical Review Team
SONORX is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
500 mg orally twice daily
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/Β΅L. Maximum dose: 10 mg/day.
Terminal elimination half-life: 12 hours (range 10-14 hours); in severe renal impairment (Cr Cl <30 m L/min) extends to 24 hours.
Terminal elimination half-life: 1.3β1.5 days (31β36 hours) in patients with ET; allows twice-daily dosing.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite N-desmethylsertraline; half-life approximately 26 hours.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal: 70% (30% unchanged, 40% as metabolites); Biliary/fecal: 20% (via CYP3A4 metabolites); Other: 10% (e.g., sweat, exhalation).
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
88% bound to albumin; minor binding to Ξ±1-acid glycoprotein.
82β88% bound to plasma proteins (primarily albumin).
1.2 L/kg (0.9-1.5 L/kg); indicates extensive tissue distribution.
30β36 L (approximately 0.45β0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral: 75% (60-85%); Subcutaneous: 90%; Intramuscular: 85%; Rectal: 50% (40-60%).
Oral: 65β80% (median 73%)
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg twice daily; GFR < 30 m L/min: 250 mg once daily; dialysis not studied
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg once daily; Child-Pugh C: not recommended
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
> 12 years: 500 mg twice daily; < 12 years: not established
Children β₯7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific adjustment; monitor renal function and reduce dose per renal guidelines
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Serotonin syndrome, activation of mania/hypomania, seizures, angle-closure glaucoma, hyponatremia, increased bleeding risk, and discontinuation syndrome.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Concurrent use with MAOIs or within 14 days of discontinuation; known hypersensitivity to SONORX; concurrent pimozide use.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid grapefruit and grapefruit juice as they may increase SONORX levels. No other specific food restrictions; maintain consistent intake of vitamin K-rich foods if on warfarin (not applicable to SONORX). Alcohol may increase bleeding risk; limit intake.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and cardiac anomalies. Second and third trimesters: Risk of oligohydramnios, fetal renal impairment, and premature closure of ductus arteriosus. Overall FDA Category X.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Excreted in human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants including renal toxicity and hypokalemia. Contraindicated during breastfeeding.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
Due to increased renal clearance and expanded plasma volume during pregnancy, dose may need to be increased by 25-50%, but risk-benefit typically prohibits use in pregnancy. No standard recommendation; alternative therapy strongly advised.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
SONORX is a novel oral anticoagulant that requires dose adjustment in renal impairment (Cr Cl <30 m L/min). Avoid concurrent use with strong CYP3A4 and P-gp inhibitors (e.g., ketoconazole, ritonavir). Monitor for signs of bleeding, especially in elderly patients or those with low body weight (<50 kg). No routine coagulation monitoring is needed. Reversal agent: idarucizumab if urgent reversal required.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/Β΅L. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take SONORX exactly as prescribed; do not stop without consulting your doctor.,Report any unusual bleeding or bruising, dark stools, or blood in urine immediately.,Inform all healthcare providers you are taking SONORX before any surgery or dental procedure.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor.,Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SONORX vs AGRYLIN, answered by our medical review team.
SONORX is a Antineoplastic agent that works by SONORX is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SONORX and AGRYLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SONORX is: 500 mg orally twice daily. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/Β΅L. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SONORX and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SONORX is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and cardiac anomalies. Second and third trimesters: Risk of oligohydramnios, fet. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.